Uromigos Live 2023 - Bladder RT
Advertisement
The panel shares predictions for the future of bladder cancer.
The panel discusses other exciting treatment advances in bladder cancer.
How the potential shift of new therapies to the frontline setting will impact subsequent treatment decisions.
The panel discussed optimal treatment cycles for enfortumab vedotin/pembrolizumab.
The panel shared their thoughts on the EV-302 study.
The panel kicked off with conversations about data released at ESMO, including EV-302 and CheckMate 901.
The panel shares their hopes for the future of bladder cancer treatment.
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
The panel shares treatment sequencing decisions based on a few patient scenarios.
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
The panel shares lessons learned from the phase THOR study.
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
The panel discusses the CheckMate 901 study results.
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
The panel discusses the "buzz" around the EV-302 study.
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.